Benjamin Bengstl

Benjamin Bengstl

Company: BioNTech

Job title: Director Immunoreceptor Therapy


A Phase I/IIa Trial to Evaluate Safety and Efficacy of CLDN6 CAR-T and CARVac Based In Vivo Expansion to Improve Treatment of Patients with CLDN6-Positive Advanced Solid Tumors 2:30 pm

Preliminary Ph1 data on FIH trial with CLDN6-CART +/- CARVac incl. safety, PK/PD and efficacy data Focus on combination with CARVac for in vivo expansion of CLDN6-CART Update on exploratory biomarker programRead more

day: Day Two

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.